Home  >> News  >> One New Anti-Infection Medicine of CP Fenghai Approved Listing

One New Anti-Infection Medicine of CP Fenghai Approved Listing

Posted by:DafengW_adminRelease time :2019-02-26Browse:

  Recently, Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. obtained the registration approval of "linezolid and glucose injection" issued by the State Drug Administration (approval number: national medicine standard No. H20183528, national medicine standard No. H20183529). The specifications are 300ml: linezolid 0.6g and glucose 15g; 100ml: linezolid 0.2g and glucose 5G. This is another anti-infective drug launched after Feng Rui Neng.

  It is understood that linezolid is the first generation of azolidinone bacterial protein synthesis inhibitor, which has a unique inhibition mode, does not affect the activity of peptide transferase and is not easy to cross-resistance; it has strong antimicrobial activity against vancomycin-resistant Enterococcus and other bacteria, and is considered as the only drug to treat vancomycin-resistant Enterococcus infection, and is considered to be the solution to methicillin-resistant Staphylococcus aureus (MRSA) infection. New directions and new hopes. At present, Zhengda Fenghai is the only domestic manufacturer of linezolid with investment model. The product has definite curative effect, large clinical demand and broad market prospects. With the recent approval of Moxifloxacin Hydrochloride and Sodium Chloride Injection, several heavy new drugs have made breakthroughs one after another, which will help Zhengda Fenghai achieve rapid development and make new strides for the realization of enterprise development. All these Steps provide strong momentum for CP Fenghai.